Pulling SEC filings + quote and writing the call…

Voyager Therapeutics, Inc.
Next earnings Aug 4, 2026 · consensus $-0.50 EPS, $6.16M rev
Last earnings -5.0% on 2026-05-07
Conservative balance sheet (liabilities/equity 0.29x); but revenue fell -49.5% YoY.
Voyager Therapeutics, Inc. shows $40.4M in FY2025 revenue (-49.5% YoY), a -296.5% net margin, and -61.1% ROE.
Sources: SEC EDGAR (CIK 0001640266, latest 10-Q filed 2026-05-07) · EODHD · as of 6/26/2026, 6:40:53 PM.
Research and education only — not financial advice. EDGAR is not a registered investment adviser or broker-dealer and gives no personalized advice. Every call is impersonal — identical for all users, generated on a schedule from SEC filings plus a delayed/third-party price feed — may be wrong or out of date, and is not a recommendation to buy or sell any security. The operator and an affiliated trading operation may hold or trade the securities EDGAR rates; see Disclosures. Past performance does not guarantee future results. Do your own research.
The risks, catalysts, 12-month price target and the cited SEC figures behind this rating — with Pro.
Unlock with Pro€15/mo · cancel anytime
| Line item | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Revenue | $37.4M | $40.9M | $250M | $80.0M | $40.4M |
| Gross profit | — | — | — | — | — |
| Operating income | -$73.6M | -$50.8M | $122M | -$83.3M | -$132M |
| Net income | -$71.2M | -$46.4M | $132M | -$65.0M | -$120M |
| Diluted EPS | -$1.89 | -$1.21 | $2.97 | -$1.13 | -$2.04 |
| Net margin | -190.3% | -113.4% | 52.9% | -81.3% | -296.5% |
Annual figures from SEC 10-K XBRL filings. Open the filing links below for full statement detail.
Computed from SEC XBRL annual figures + the current quote. EV and ROIC use long-term + current debt where filed; estimates, not investment advice.
1047 tracked peers · median
Dates from 8-K (Item 2.02); beat/miss = reported EPS vs consensus (Finnhub, recent quarters); move = prior close → close on/after.
Recent news tone vs the market's typical (which skews positive). A soft signal, not a recommendation.